Literature DB >> 34272498

Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases.

Domenica Lovero1, Stella D'Oronzo1, Raffaele Palmirotta1, Paola Cafforio1, Janet Brown2, Steven Wood2, Camillo Porta1, Eleonora Lauricella1, Robert Coleman2, Franco Silvestris3.   

Abstract

BACKGROUND: Bone is the most frequent site of metastases from breast cancer (BC), but no biomarkers are yet available to predict skeletal dissemination.
METHODS: We attempted to identify a gene signature correlated with bone metastasis (BM) onset in circulating tumour cells (CTCs), isolated by a DEPArray-based protocol from 40 metastatic BC patients and grouped according to metastasis sites, namely "BM" (bone-only), "ES" (extra-skeletal) or BM + ES (bone + extra-skeletal).
RESULTS: A 134-gene panel was first validated through targeted RNA sequencing (RNAseq) on sub-clones of the MDA-MB-231 BC cell line with variable organotropism, which successfully shaped their clustering. The panel was then applied to CTC groups and, in particular, the "BM" vs "ES" CTC comparison revealed 31 differentially expressed genes, including MAF, CAPG, GIPC1 and IL1B, playing key prognostic roles in BC.
CONCLUSION: Such evidence confirms that CTCs are suitable biological sources for organotropism investigation through targeted RNAseq and might deserve future applications in wide-scale prospective studies.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34272498      PMCID: PMC8810805          DOI: 10.1038/s41416-021-01481-z

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  58 in total

Review 1.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 2.  Multigene assays in early breast cancer: Insights from recent phase 3 studies.

Authors:  C Markopoulos; D M Hyams; H L Gomez; M Harries; S Nakamura; T Traina; A Katz
Journal:  Eur J Surg Oncol       Date:  2019-10-15       Impact factor: 4.424

Review 3.  Liquid biopsy in breast cancer: A comprehensive review.

Authors:  Sahar Alimirzaie; Maryam Bagherzadeh; Mohammad R Akbari
Journal:  Clin Genet       Date:  2019-02-27       Impact factor: 4.438

4.  Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.

Authors:  Bernardo Amadeo Leone; Carlos Teodoro Vallejo; Alberto Omar Romero; Mario Raúl Machiavelli; Juan Eduardo Pérez; Julieta Leone; José Pablo Leone
Journal:  Breast Cancer Res Treat       Date:  2016-12-14       Impact factor: 4.872

Review 5.  The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Authors:  Massimo Cristofanilli; Jean-Yves Pierga; James Reuben; Alfred Rademaker; Andrew A Davis; Dieter J Peeters; Tanja Fehm; Franco Nolé; Rafael Gisbert-Criado; Dimitrios Mavroudis; Salvatore Grisanti; Mario Giuliano; Jose A Garcia-Saenz; Justin Stebbing; Carlos Caldas; Paola Gazzaniga; Luis Manso; Rita Zamarchi; Angela Fernandez de Lascoiti; Leticia De Mattos-Arruda; Michail Ignatiadis; Luc Cabel; Steven J van Laere; Franziska Meier-Stiegen; Maria-Teresa Sandri; Jose Vidal-Martinez; Eleni Politaki; Francesca Consoli; Daniele Generali; Maria Rosa Cappelletti; Eduardo Diaz-Rubio; Jonathan Krell; Sarah-Jane Dawson; Cristina Raimondi; Annemie Rutten; Wolfgang Janni; Elisabetta Munzone; Vicente Carañana; Sofia Agelaki; Camillo Almici; Luc Dirix; Erich-Franz Solomayer; Laura Zorzino; Lauren Darrigues; Jorge S Reis-Filho; Lorenzo Gerratana; Stefan Michiels; François-Clément Bidard; Klaus Pantel
Journal:  Crit Rev Oncol Hematol       Date:  2018-12-19       Impact factor: 6.312

6.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

7.  Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences.

Authors:  Stella D'Oronzo; Walter Gregory; Simon Nicholson; Yuen Khong Chong; Janet Brown; Robert Coleman
Journal:  J Bone Oncol       Date:  2021-05-04       Impact factor: 4.072

8.  Circulating Tumor Cells in Early Breast Cancer.

Authors:  Laura Thery; Alessandra Meddis; Luc Cabel; Charlotte Proudhon; Aurelien Latouche; Jean-Yves Pierga; Francois-Clement Bidard
Journal:  JNCI Cancer Spectr       Date:  2019-04-27

Review 9.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.

Authors:  Ru Wang; Yayun Zhu; Xiaoxu Liu; Xiaoqin Liao; Jianjun He; Ligang Niu
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

View more
  3 in total

Review 1.  The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis.

Authors:  Giorgio Ivan Russo; Nicolò Musso; Alessandra Romano; Giuseppe Caruso; Salvatore Petralia; Luca Lanzanò; Giuseppe Broggi; Massimo Camarda
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

2.  Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis.

Authors:  Daniel Brian Shropshire; Francisca M Acosta; Kun Fang; Jaime Benavides; Lu-Zhe Sun; Victor X Jin; Jean X Jiang
Journal:  Front Med (Lausanne)       Date:  2022-09-15

Review 3.  Differential Intracellular Protein Distribution in Cancer and Normal Cells-Beta-Catenin and CapG in Gynecologic Malignancies.

Authors:  Maria Kristha Fernandez; Molika Sinha; Malte Renz
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.